Neurogene Inc NGNE
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-03-07 |
| Shares Out. | 19,740,000 |
| Website | neurogene.com/ ↗ |
| Phone | 13026587581 |
| Employees | 131 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$34.5M |
| Free Cash Flow | -$87.7M |
| Total Assets | $244.4M |
| Total Liabilities | $27.2M |
| Equity | $217.1M |
About Neurogene Inc
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Neurogene Inc is a publicly traded company under the ticker symbol NGNE on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-09-01)